AGP Executive Report
Last update: 3 hours agoMedicare GLP-1 Shift: Medicare is launching a temporary “GLP-1 Bridge” pilot starting July 1, letting eligible beneficiaries access weight-loss drugs like Zepbound and Wegovy with a $50-a-month co-pay, but with prior authorization and a planned end by Dec. 31, 2027. Medicaid Work Requirements Fallout: States and health centers are bracing for major Medicaid changes tied to new work rules, with experts warning of coverage losses, more uninsured patients, and system-wide cost pressure. Cancer & Rare Disease Pipeline: FDA authorized use of the clonoSEQ MRD test in Imviva’s TENACITY-01 CAR-T trial; Monopar received Rare Pediatric Disease designation for ALXN1840 in Wilson disease; and Quoin won a key patent notice for a Netherton syndrome combination therapy. Pain & Delivery Tech: Dogwood added a scientific advisory board chair to advance non-opioid pain programs, while Microbot expanded manufacturing capacity for its LIBERTY robotic system via Sanmina. Healthcare Access & Ops: Ally Medical opened an ER in Cedar Park, and Nebraska Medicine’s governance transition begins July 1 with equal voting representation during a temporary period. Pharma Integrity Watch: NEJM retracted an Amgen Tavneos paper after FDA-linked concerns about trial data handling.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
